Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
